Ratings
0
Nobody has rated this yet. Be the first!
Works
2
A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.
